Jazz Phase III Success With Xywav In Idiopathic Hypersomnia Strengthens A Valuable Franchise
Executive Summary
The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.
You may also be interested in...
Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
All Eyes On Pfizer For More Details On COVID-19 Vaccine Launch
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.
Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds
Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.
Need a specific report? 1000+ reports available
Buy Reports